{"prompt": "['38', 'MC1488 WEE1', 'MCCC', 'Use the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0* unless', 'otherwise specified <<', 'CTCAE', 'System/Organ/Class', 'ADVERSE EVENT', 'AGENT', 'ACTION**', '(SOC)', 'Non Hematologic', 'All Non-Hematologic', 'AZD1775', 'Hold AZD1775 and AraC. Re-check', 'Toxicities', 'patient at weekly or at least every other', 'Grade > 4 (With the', 'week. When event returns to grade 2,', 'exception of nausea,', 'resume AZD1775 and AraC', 'vomiting or diarrhea', 'treatment at next lower dose level.', 'controlled with', 'appropriate', 'medications.)', '*', 'Located at http:/ctep.cancer.gov/protocolDevelopment/electronic applications.ctc.htm', '**', 'Use the following to describe actions in the Action column:', 'Omit = Treatment is not given for the day that is omitted, but treatment may resume once', 'the adverse event has resolved as mandated in Table 8.2. For example, if treatment is', 'omitted on Day 8, but the adverse event has resolved by Day 10, treatment may resume', 'on Day 10 to complete the cycle. Missed doses will not be made up.', 'Hold/Delay = Treatment can be made up as part of this cycle', 'Discontinue = Treatment is totally stopped', '*** AraC can be continued each cycle regardless of dose hold or adjustments for AZD1775, if patient is', 'presumed to derive clinical benefit from the intervention.', 'Patients whose treatment is interrupted or permanently discontinued due to an adverse event including', 'abnormal laboratory values must be followed by their treating physician as clinically indicated. The', 'maximum time allowed for treatment interruption due to toxicity is 6 weeks from the intended dosing', 'day. If interruption is > 6 weeks, continuation of treatment is allowed on a case by case basis (i.e. clinical', 'benefit) as determined by the treating physician. However, the patient will continue to be followed for', 'toxicity. Dose interruptions should be reported on the appropriate Dosage Administration CRF.', '9.0', 'Ancillary Treatment/Supportive Care/Concomitant Medications', '9.1', 'Routine use of colony-stimulating factors (G-CSF or GM-CSF) is not recommended.', 'Prophylactic use of colony-stimulating factors should be discussed with the study chair.', 'Therapeutic use in patients with serious neutropenic complications may be considered at', 'physician discretion. Recombinant erythropoietin to maintain adequate hemoglobin', 'levels is discouraged and only allowed after discussion with the study chair.', '9.2', 'Patients should receive full supportive care while on this study. This includes blood', 'product support, antibiotic treatment and treatment of other newly diagnosed or', 'concurrent medical conditions. All blood products and concomitant medications such as', 'antidiarrheals, analgesics, anti-emetics received from the first administration of study', 'drugs until 30 days after the final dose are to be recorded in the medical record. For more', 'severe diarrhea (i.e. Grade 3 or 4) supportive measures such as hydration and anti-', 'diarrheals are recommended according to instutitional practice guidelines and as deemed', 'appropriate by the medical situation (i.e. IV rehydration as in- or outpatient, antibiotics).', '9.3', 'Anti-emetic therapy (excluding aprepitant) may be used in accordance with standard', 'practice and/or the discretion of the investigator.']['39', 'MC1488 WEE1', 'MCCC', '9.4', 'Hydroxyurea is allowed during the trial to control blast counts/WBC if the patient is felt', 'to derive benefit from study treatment.', '9.5', 'Patients on metformin should be closely watched for elevated metformin levels that could', 'put them at risk for hypoglycemia.', '10.0', 'Adverse Event (AE) Reporting and Monitoring', '10.1', 'Adverse Event Characteristics', 'CTCAE term (AE description) and grade: The descriptions and grading scales found', 'in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version', '4.0 will be utilized for AE reporting. All appropriate treatment areas should have access', 'to a copy of the CTCAE version 4.0. A copy of the CTCAE version 4.0 can be', 'downloaded from the CTEP web site:', 'http://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm)', '10.11', 'Adverse event monitoring and reporting is a routine part of every clinical trial.', 'First, identify and grade the severity of the event using the CTCAE version 4.0.', 'Next, determine whether the event is expected or unexpected (see Section 10.2)', 'and if the adverse event is related to the medical treatment or procedure (see', 'Section 10.3). With this information, determine whether the event must be', 'reported as an expedited report (see Section 10.4). Expedited reports are to be', 'completed within the timeframes and via the mechanisms specified in Section', '10.4. All AEs reported via expedited mechanisms must also be reported via the', 'routine data reporting mechanisms defined by the protocol (see Sections 10.6 and', '18.0).', '10.12 Each CTCAE term in the current version is a unique representation of a specific event', 'used for medical documentation and scientific analysis and is a single MedDRA', 'Lowest Level Term (LLT). Grade is an essential element of the Guidelines and, in', 'general, relates to severity for the purposes of regulatory reporting to NCI.', 'NOTE: A severe AE, as defined by the above grading scale, is NOT the same', 'as serious AE which is defined in the table in Section 10.4.', '10.13 Medical conditions/diseases present before starting study treatment are only', 'considered adverse events if they worsen after starting study treatment (any', 'procedures specified in the protocol). Adverse events occurring before starting', 'study treatment but after signing the informed consent form are not recorded.', 'Abnormal laboratory values or test results constitute adverse events only if they', 'induce clinical signs or symptoms or require therapy, and are recorded.', '10.14', 'Any serious adverse event occurring after the patient has provided informed', 'consent, has started taking the study medication, and until 4 weeks after the', 'patient has stopped study participation must be reported. This includes the period', 'in which the study protocol interferes with the standard medical treatment given', 'to a patient (e.g. treatment withdrawal during washout period, change in', 'treatment to a fixed dose of concomitant medication). The period after', 'discontinuing study drug may be extended if there is a strong suspicion that the']\n\n###\n\n", "completion": "END"}